Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01165996 · ClinicalTrials.gov registry record · Phase 1
Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome
A Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT01165996 is a Phase 1 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 25 participants.
The verdict
NCT01165996, a Phase 1 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
RATIONALE: Decitabine may help myelodysplastic cells become more like normal stem cells. PURPOSE: This clinical trial studies differentiation therapy with decitabine in treating patients with myelodysplastic syndrome.
Interventions
- GENETIC microarray analysis
- DRUG decitabine
- OTHER flow cytometry
- OTHER DNA methylation analysis
- OTHER cytogenetic analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01165996
The ClinicalTrials.gov registry entry for NCT01165996 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which microarray analysis is the first listed.
NCT01165996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01165996 about?
NCT01165996 is a clinical study titled "Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome". RATIONALE: Decitabine may help myelodysplastic cells become more like normal stem cells. PURPOSE: This clinical trial studies differentiation therapy with decitabine in treating patients with myelodysplastic syndrome.
What is the current status of trial NCT01165996?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2010-07. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01165996?
The interventions under investigation include: microarray analysis (GENETIC), decitabine (DRUG), flow cytometry (OTHER), DNA methylation analysis (OTHER), cytogenetic analysis (OTHER).
Who is sponsoring clinical trial NCT01165996?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.